Advanced search
Publication Cover
Gut Microbes Volume 15, 2023 - Issue 1
Submit an article Journal homepage
19,594
Views
46
CrossRef citations to date
0
Altmetric
Review

Emerging issues in probiotic safety: 2023 perspectives

Daniel Merensteina Department of Family Medicine, Georgetown University Medical Center, Washington, DCUSAORCID Iconhttps://orcid.org/0000-0002-8808-6907View further author information
ORCID Icon,
Bruno Potb Yakult Europe BV, Almere, NetherlandsORCID Iconhttps://orcid.org/0000-0001-5995-6929View further author information
ORCID Icon,
Gregory Leyerc Scientific Affairs, Chr. Hansen, Milwaukee, WI, USAORCID Iconhttps://orcid.org/0000-0003-1745-4343View further author information
ORCID Icon,
Arthur C. Ouwehandd Global Health & Nutrition Sciences, International Flavors & Fragrances, Kantvik, FinlandORCID Iconhttps://orcid.org/0000-0001-8348-0633View further author information
ORCID Icon,
Geoffrey A. Preidise Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-2206-6452View further author information
ORCID Icon,
Christopher A. Elkinsf Clinical and Environmental Microbiology Branch, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAORCID Iconhttps://orcid.org/0000-0002-6029-9812View further author information
ORCID Icon,
Colin Hillg APC Microbiome Ireland, University College Cork, Cork, IrelandORCID Iconhttps://orcid.org/0000-0002-8527-1445View further author information
ORCID Icon,
Zachery T. Lewish Synbiotic Health Inc, Lincoln, NE, USAORCID Iconhttps://orcid.org/0000-0002-7725-2869View further author information
ORCID Icon,
Andi L. Shanei Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Emory Children’s Center, Atlanta, GeorgiaORCID Iconhttps://orcid.org/0000-0003-0606-7188View further author information
ORCID Icon,
Niv Zmoraj Scientific consultant, Elinav Lab, Immunology Department, Weizmann Institute of Science, Department of Gastroenterology and Liver Diseases, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0001-7928-316XView further author information
ORCID Icon,
Mariya I. Petrovak Winclove Probiotics B.V., Amsterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-0840-5294View further author information
ORCID Icon,
Maria Carmen Colladol Institute of Agrochemistry and Food Technology-National Research Council (IATA-CSIC), Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-6204-4864View further author information
ORCID Icon,
Lorenzo Morellim Department of Food Science and Technology, Università Cattolica del Sacro Cuore, Piacenza, ItalyORCID Iconhttps://orcid.org/0000-0003-0475-2712View further author information
ORCID Icon,
Gina A. Montoyan Department of Chemical Risk Assessment, Nestlé S.A., Lausanne, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-2848-1339View further author information
ORCID Icon,
Hania Szajewskao Department of Paediatrics, The Medical University of Warsaw, Warsaw, PolandORCID Iconhttps://orcid.org/0000-0002-4596-2874View further author information
ORCID Icon,
Daniel J. Tancredip Department of Pediatrics, UC Davis School of Medicine, Sacramento, CA, USAORCID Iconhttps://orcid.org/0000-0002-3884-7907View further author information
ORCID Icon &
Mary Ellen Sandersq International Scientific Association for Probiotics and Prebiotics, Centennial, CO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6321-3423View further author information
ORCID Icon show all
Article: 2185034 | Received 30 Dec 2022, Accepted 22 Feb 2023, Published online: 15 Mar 2023

References

  • Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–22. doi:10.1038/nrgastro.2014.66.
  • Mogensen G, Salminen S, O’brien J, Ouwehand AC, Holzapfel W, Shortt C, et al. Food microorganisms - health benefits, safety evaluation and strains with documented history of use in foods. Bulletin of the IDF. 2002;377:4–9.
  • Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12: CD006095. doi:10.1002/14651858.CD006095.pub4.
  • Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4: CD004827. doi:10.1002/14651858.CD004827.pub5.
  • Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011;200:1–645.
  • Sanders ME, Merenstein DJ, Ouwehand AC, Reid G, Salminen S, Cabana MD, Paraskevakos G, Leyer G. Probiotic use in at-risk populations. J Am Pharm Assoc. 2003 2016;56(6):680–686. doi:10.1016/j.japh.2016.07.001.
  • van den Nieuwboer M, Claassen E. Dealing with the remaining controversies of probiotic safety. Benef Microbes. 2019;10(6):605–616. doi:10.3920/BM2018.0159.
  • Hill C. Balancing the risks and rewards of live biotherapeutics. Nat Rev Gastroenterol Hepatol. 2020;17(3):133–134. doi:10.1038/s41575-019-0254-3.
  • Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Girgis H, Harper A, Lavergne SN, Mathys S, Pane M, et al. Live biotherapeutic products, a road map for safety assessment. Front Med (Lausanne). 2020;7:237. doi:10.3389/fmed.2020.00237.
  • Zuntar I, Petric Z, Bursac Kovacevic D, Putnik P. Safety of probiotics: functional fruit beverages and nutraceuticals. Foods. 2020;9(7):947. doi:10.3390/foods9070947.
  • Koutsoumanis K, Allende A, Alvarez‐ordóñez A, Bolton D, Bover-cid S, Chemaly M, Davies R, De Cesare A, Hilbert F, Lindqvist R, et al. Update of the list of QPS-recommended microbiological agents intentionally added to food or feed as notified to EFSA 16: suitability of taxonomic units notified to EFSA until march 2022. EFSAJ. (2022), 20(7). 2022. doi:https://doi.org/10.2903/j.efsa.2022.7408.
  • Pariza MW, Gillies KO, Kraak-Ripple SF, Leyer G, Smith AB. Determining the safety of microbial cultures for consumption by humans and animals. Regul Toxicol Pharmacol. 2015;73(1):164–171. doi:10.1016/j.yrtph.2015.07.003.
  • Holzapfel W, Arini A, Aeschbacher M, Coppolecchia R, Pot B. Enterococcus faecium SF68 as a model for efficacy and safety evaluation of pharmaceutical probiotics. Benef Microbes. 2018;9(3):375–388. doi:10.3920/BM2017.0148.
  • Roe AL, Boyte ME, Elkins CA, Goldman VS, Heimbach J, Madden E, Oketch-Rabah H, Sanders ME, Sirois J, Smith A. Considerations for determining safety of probiotics: a USP perspective. Regul Toxicol Pharmacol. 2022;136:105266. doi:10.1016/j.yrtph.2022.105266.
  • Cohen PA. Probiotic safety—no guarantees. JAMA Intern Med. 2018;178(12):1577–1578. doi:10.1001/jamainternmed.2018.5403.
  • Freedman SB, Schnadower D, Tarr PI. The probiotic conundrum: regulatory confusion, conflicting ctudies, and safety concerns. JAMA. 2020;323(9):823–824. doi:10.1001/jama.2019.22268.
  • Poindexter B, Committee on F, Hand, Newborn I, Adams-Chapman I, Aucott SW, Puopolo KM, Goldsmith JP, Kaufman D, Martin C, et al. Use of probiotics in preterm infants. Pediatrics. 2021; 147(6). doi:10.1542/peds.2021-051485.
  • Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, Venditti M. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41(11):5340–5343. doi:10.1128/JCM.41.11.5340-5343.2003.
  • Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, Berche P. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19(1):16–20. doi:10.1007/s100960050003.
  • Bongaerts GPA, Severijnen RSVM. A reassessment of the PROPATRIA study and its implications for probiotic therapy. Nat Biotechnol. 2016;34(1):55–63. doi:10.1038/nbt.3436.
  • Cabana MD, Salminen S, Sanders ME. Probiotic safety—reasonable certainty of no harm. JAMA Intern Med. 2019;179(2):276. doi:10.1001/jamainternmed.2018.7498.
  • Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, Morgan RL. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697–705. doi:10.1053/j.gastro.2020.05.059.
  • Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. doi:10.1038/s41591-019-0439-x.
  • Suez J, Zmora N, Elinav E. Probiotics in the next-generation sequencing era. Gut Microbes. 2020;11(1):77–93. doi:10.1080/19490976.2019.1586039.
  • Wm DV, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020–1032. doi:10.1136/gutjnl-2021-326789.
  • Zhang C, Derrien M, Levenez F, Brazeilles R, Ballal SA, Kim J, Degivry M-C, Quéré G, Garault P, van Hylckama Vlieg JET, et al. Ecological robustness of the gut microbiota in response to ingestion of transient food-borne microbes. Isme J. 2016;10(9):2235–2245. doi:10.1038/ismej.2016.13.
  • Ray KJ, Santee C, McCauley K, Panzer AR, Lynch SV. Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis. BMC Pulm Med. 2022;22(1):287. doi:10.1186/s12890-022-02078-9.
  • Chang CM, Tsai MH, Liao WC, Yang PH, Li SW, Chu SM, Huang H-R, Chiang M-C, Hsu J-F. Effects of probiotics on gut microbiomes of extremely preterm infants in the neonatal intensive care unit: a prospective cohort study. Nutrients. 2022;14(15):3239. doi:10.3390/nu14153239.
  • Samara J, Moossavi S, Alshaikh B, Ortega VA, Pettersen VK, Ferdous T, Hoops SL, Soraisham A, Vayalumkal J, Dersch-Mills D, et al. Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host Microbe. 2022;30(5):696–711 e5. doi:10.1016/j.chom.2022.04.005.
  • Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med. 2018;169(4):240–247. doi:10.7326/M18-0343.
  • Food and Agricultural Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. https://www.fao.org/3/a0512e/a0512e.pdf.
  • Food and Agricultural Organization of the United Nations and World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. https://www.fao.org/3/a0512e/a0512e.pdf.
  • Morelli L, Sarra PG, Bottazzi V. In vivo transfer of pAmβ1 from Lactobacillus reuteri to Enterococcus faecalis. J Appl Bacteriol. 1988;65(5):371–375. doi:10.1111/j.1365-2672.1988.tb01905.x.
  • Crits-Christoph A, Hallowell HA, Koutouvalis K, Suez J. Good microbes, bad genes? the dissemination of antimicrobial resistance in the human microbiome. Gut Microbes. 2022;14(1):2055944. doi:10.1080/19490976.2022.2055944.
  • WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance. Critically important antimicrobials for human medicine. 2018. https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf.
  • World Health Organization. The WHO essential medicines list antibiotic book: improving antibiotic AWaReness. 2022. https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf.
  • European Food Safety Authority. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA J. 2012;10(6):2012. doi:10.2903/j.efsa.2012.2740.
  • Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10(2):165. doi:10.3390/pathogens10020165.
  • Technical committee: iSO/TC 34/SC 5. Milk and milk products — determination of the minimal inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and non-enterococcal lactic acid bacteria (LAB). USI. 10932.2010.
  • Impey RE, Hawkins DA, Sutton JM, Soares da Costa TP. Overcoming intrinsic and acquired resistance mechanisms associated with the cell wall of gram-negative bacteria. Antibiotics (Basel). 2020;9(9). doi:10.3390/antibiotics9090623.
  • Elkins CA, Mullis LB. Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid. Appl Environ Microbiol. 2004;70(12):7200–7209. doi:10.1128/AEM.70.12.7200-7209.2004.
  • Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29(3):654–669. doi:10.1002/pro.3819.
  • Stefanska I, Kwiecien E, Jozwiak-Piasecka K, Garbowska M, Binek M, Rzewuska M. Antimicrobial susceptibility of lactic acid bacteria strains of potential use as feed additives - the basic safety and usefulness criterion. Front Vet Sci. 2021;8:687071. doi:10.3389/fvets.2021.687071.
  • Morelli L, Matto J, Wilcks A, Aarts HJM, Bolton D. ACE-ART EU project for the evaluation of antibiotic resistance transferability in the food chain. NUTRAfoods. 2005;4:89–93.
  • U.S. Food & Drug Administration. GRN No. 49. Bifidobacterium lactis strain Bb12 and streptococcus thermophilus strain Th4. 2005. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=49&sort=GRN_No&order=DESC&startrow=1&type=basic&search=bifidobacterium
  • McInnes RS, McCallum GE, Lamberte LE, van Schaik W. Horizontal transfer of antibiotic resistance genes in the human gut microbiome. Curr Opin Microbiol. 2020;53:35–43. doi:10.1016/j.mib.2020.02.002.
  • Winter M, Buckling A, Harms K, Johnsen PJ, Vos M. Antimicrobial resistance acquisition via natural transformation: context is everything. Curr Opin Microbiol. 2021;64:133–138. doi:10.1016/j.mib.2021.09.009.
  • Cj VW, Penders J, Jm VN, Nd M, Majumder S, Lb VA, Savelkoul PHM, Wolffs PFG. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front Microbiol. 2016;7:173. doi:10.3389/fmicb.2016.00173.
  • Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667. doi:10.1038/s41575-021-00440-6.
  • European Food Safety Authority. Scientific opinion on the safety of pasteurised akkermansia muciniphila as a novel food pursuant to regulation (EU) 2015/2283. EFSA J. 2021;19(9). doi:10.2903/j.efsa.2021.6780.
  • EFSA Panel on Nutrition NFaFAN. Safety of pasteurisedAkkermansia muciniphilaas a novelfood pursuant to Regulation (EU) 2015/2283. EFSA J. 2021;19:6780.
  • Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen ALV, Cheng AA, Liu S, et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48:D517–25. doi:10.1093/nar/gkz935.
  • National Institutes of Health. National Database of Antibiotic Resistant Organisms (NDARO). National Library of Medicine; 2022. https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/
  • Montassier E, Valdes-Mas R, Batard E, Zmora N, Dori-Bachash M, Suez J, Elinav E. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner. Nat Microbiol. 2021;6:1043–1054. doi:10.1038/s41564-021-00920-0.
  • Guitor AK, Yousuf EI, Raphenya AR, Hutton EK, Morrison KM, McArthur AG, Wright GD, Stearns JC. Capturing the antibiotic resistome of preterm infants reveals new benefits of probiotic supplementation. Microbiome. 2022;10(1):136. doi:10.1186/s40168-022-01327-7.
  • Campbell-Platt G. Fermented foods — a world perspective. Int Food Res J. 1994;27(3):253–257. doi:10.1016/0963-9969(94)90093-0.
  • Maeusli M, Lee B, Miller S, Reyna Z, Lu P, Yan J, et al.Horizontal gene transfer of antibiotic resistance from acinetobacter baylyi to escherichia coli on lettuce and subsequent antibiotic resistance transmission to the gut microbiome mSphere 2020; 5.10.1128/mSphere.00329-20.
  • D’agostin M, Squillaci D, Lazzerini M, Barbi E, Wijers L, Da Lozzo P. Invasive infections associated with the use of probiotics in children: a systematic review. Children (Basel). 2021;8(10):924. doi:10.3390/children8100924.
  • Morgan RL, Preidis GA, Kashyap PC, Weizman AV, Sadeghirad B, McMaster Probiotic P, Florez ID, Foroutan F, Shahid S, Zeraatkar D. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology. 2020;159(2):467–480. doi:10.1053/j.gastro.2020.05.096.
  • Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2017;179:204–222. doi:10.1016/j.trsl.2016.08.002.
  • Dashnyam P, Mudududdla R, Hsieh TJ, Lin TC, Lin HY, Chen PY, Hsu C-Y, Lin C-H. β-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut. Sci Rep. 2018;8(1):16372. doi:10.1038/s41598-018-34678-z.
  • Carmody RN, Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest. 2014;124(10):4173–4181. doi:10.1172/JCI72335.
  • Gingell R, Bridges JW. Intestinal azo reduction and glucuronide conjugation of prontosil. Biochem J. 1971;125(2):24. doi:10.1042/bj1250024Pa.
  • Chung KT, Stevens SE Jr., Cerniglia CE. The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol. 1992;18(3):175–190. doi:10.3109/10408419209114557.
  • Klaassen CD, Cui JY. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos. 2015;43(10):1505–1521. doi:10.1124/dmd.115.065698.
  • Pant A, Maiti TK, Mahajan D, Das B. Human gut microbiota and drug metabolism. Microb Ecol. 2022. doi:10.1007/s00248-022-02081-x.
  • Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science. 2019; 364(6445). doi:10.1126/science.aau6323.
  • Atashgahi S, Shetty SA, Smidt H, de Vos WM. Flux, impact, and fate of halogenated xenobiotic compounds in the gut. Front Physiol. 2018;9:888. doi:10.3389/fphys.2018.00888.
  • Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, et al. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 2017;49(2):105–138. doi:10.1080/03602532.2017.1293682.
  • Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: the human microbiome vs. pharmaceutical, dietary, and environmental xenobiotics. Front Pharmacol. 2020;11:390. doi:10.3389/fphar.2020.00390.
  • Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Ma A. Pharmacomicrobiomics: influence of gut microbiota on drug and xenobiotic metabolism. Faseb J. 2022;36(6):e22350. doi:10.1096/fj.202101986R.
  • Candeliere F, Raimondi S, Ranieri R, Musmeci E, Zambon A, Amaretti A, Rossi M.β-Glucuronidase pattern predicted from gut metagenomes indicates potentially diversified pharmacomicrobiomics.Front Microbiol.2022.13.10.3389/fmicb.2022.826994.
  • Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein & Cell. 2018;9(5):432–445. doi:10.1007/s13238-018-0547-2.
  • Hassan M, Awan FM, Naz A, DeAndres-Galiana EJ, Alvarez O, Cernea A, Fernández-Brillet L, Fernández-Martínez JL, Kloczkowski A. Innovations in genomics and big data analytics for personalized medicine and health care: a review. Int J Mol Sci. 2022;23(9):4645. doi:10.3390/ijms23094645.
  • Sanders ME, Heimbach JT, Pot B, Tancredi DJ, Lenoir-Wijnkoop I, Lahteenmaki-Uutela A, Gueimonde M, Bañares S. Health claims substantiation for probiotic and prebiotic products. Gut Microbes. 2011;2(3):127–133. doi:10.4161/gmic.2.3.16174.
  • Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? Eur J Clin Nutr. 2019;73(1):24–37. doi:10.1038/s41430-018-0135-9.
  • van Schaik W. Baas becking meets one health. Nat Microbiol. 2022;7(4):482–483. doi:10.1038/s41564-022-01100-4.
  • Tachon S, Lee B, Marco ML. Diet alters probiotic Lactobacillus persistence and function in the intestine. Environ Microbiol. 2014;16(9):2915–2926. doi:10.1111/1462-2920.12297.
  • Rattanaprasert M, Roos S, Hutkins RW, Walter J. Quantitative evaluation of synbiotic strategies to improve persistence and metabolic activity of Lactobacillus reuteri DSM 17938 in the human gastrointestinal tract. J Funct Foods. 2014;10:85–94. doi:10.1016/j.jff.2014.05.017.
  • Krumbeck JA. Characterization of the role of host and dietary factors in the establishment of bacteria in the gastrointestinal tract. Diss Theses Biol Sci. 2016;87.
  • Aggarwala V, Mogno I, Li Z, Yang C, Britton GJ, Chen-Liaw A, Mitcham J, Bongers G, Gevers D, Clemente JC, et al. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nat Microbiol. 2021;6:1309–1318. doi:10.1038/s41564-021-00966-0.
  • Taverniti V, Koirala R, Dalla via A, Gargari G, Leonardis E, Arioli S, Guglielmetti S. Effect of cell concentration on the persistence in the human intestine of four probiotic strains administered through a multispecies formulation. Nutrients. 2019;11(2):11. doi:10.3390/nu11020285.
  • Maldonado-Gomez MX, Martinez I, Bottacini F, O’callaghan A, Ventura M, van Sinderen D, Hillmann B, Vangay P, Knights D, Hutkins R, et al. Stable engraftment of bifidobacterium longum ah1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe. 2016;20(4):515–526. doi:10.1016/j.chom.2016.09.001.
  • Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, Eid J, Gines J, Iyer M, Justice N, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020;8(1):8. doi:10.1136/bmjdrc-2020-001319.
  • O’brien CE, Meier AK, Cernioglo K, Mitchell RD, Casaburi G, Frese SA, Henrick BM, Underwood MA, Smilowitz JT. Early probiotic supplementation with B. infantis in breastfed infants leads to persistent colonization at 1 year. Pediatr Res. 2022;91(3):627–636. doi:10.1038/s41390-020-01350-0.
  • Frese SA, Hutton AA, Contreras LN, Shaw CA, Palumbo MC, Casaburi G, et al.Persistence of supplemented Bifidobacterium longum subsp. infantis EVC001 in breastfed infants mSphere 2017; 2.10.1128/mSphere.00501-17.
  • Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, Baccaglini L, Mohapatra A, Mohapatra SS, Misra PR, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017;548(7668):407–412. doi:10.1038/nature23480.
  • Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, et al. Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906–1915. doi:10.1056/NEJMoa1915254.
  • Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol. 2002;9(1):92–96. doi:10.1128/CDLI.9.1.92-96.2002.
  • Invernici MM, Salvador SL, Silva PHF, Soares MSM, Casarin R, Palioto DB, Souza SLS, Taba M, Novaes AB, Furlaneto FAC, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. J Clin Periodontol. 2018;45(10):1198–1210. doi:10.1111/jcpe.12995.
  • Myles IA, Moore IN, Castillo CR, Datta SK. Differing virulence of healthy skin commensals in mouse models of infection. Front Cell Infect Microbiol. 2018;8:451. doi:10.3389/fcimb.2018.00451.
  • Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, Hinkle M, Lesho E, McGann P, McAdam AJ, et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019;25(11):1728–1732. doi:10.1038/s41591-019-0626-9.
  • Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406–23 e16. doi:10.1016/j.cell.2018.08.047.
  • Grazul H, Kanda LL, Gondek D. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes. 2016;7(2):101–114. doi:10.1080/19490976.2016.1138197.
  • Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017;8(1):17–32. doi:10.1080/19490976.2016.1267890.
  • Castagnoli R, Pala F, Bosticardo M, Licari A, Delmonte OM, Villa A, Marseglia GL, Notarangelo LD. Gut microbiota–host interactions in inborn errors of immunity. Int J Mol Sci. 2021;22(3):1416. doi:10.3390/ijms22031416.
  • Dorato MA, Buckley LA. Toxicology testing in drug discovery and development. Curr Protoc Toxicol. 2007;31(1). 19.1.1-.1.35. doi:10.1002/0471141755.tx1901s31.
  • Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. 2022. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
  • D’amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf. 2020;19(7):807–816. doi:10.1080/14740338.2020.1773430.
  • Colerangle JB. Chapter 25 - preclinical development of nononcogenic drugs (small and large molecules). In: Faqi A editor. A comprehensive guide to toxicology in nonclinical drug development. Second. Boston: Academic Press; 2017. pp. 659–683.
  • U.S. Food and drug administration, center for food safety and applied nutrition, office of food additive safety. Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents. 2007. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5a-chronic-toxicity-studies-rodents
  • Veiga P, Suez J, Derrien M, Elinav E. Moving from probiotics to precision probiotics. Nat Microbiol. 2020;5(7):878–880. doi:10.1038/s41564-020-0721-1.
  • Bilal M, Ashraf S, Zhao X. Dietary component-induced inflammation and its amelioration by prebiotics, probiotics, and synbiotics. Front Nutr. 2022;9:931458. doi:10.3389/fnut.2022.931458.
  • Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hormannsperger G, Huys G. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164–185. doi:10.4161/gmic.1.3.12127.
  • Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: a review. Biomed Pharmacother. 2019;111:537–547. doi:10.1016/j.biopha.2018.12.104.
  • Doern CD, Nguyen ST, Afolabi F, Burnham CA, Carroll KC. Probiotic-associated aspiration pneumonia due to Lactobacillus rhamnosus. J Clin Microbiol. 2014;52(8):3124–3126. doi:10.1128/JCM.01065-14.
  • Shinar E, Leitersdorf E, Yevin R. Lactobacillus plantarum endocarditis. Klin Wochenschr. 1984;62(24):1173–1174. doi:10.1007/BF01712185.
  • Ze-Ze L, Tenreiro R, Duarte A, Salgado MJ, Melo-Cristino J, Lito L, et al. Case of aortic endocarditis caused by Lactobacillus casei. J Med Microbiol. 2004;53(5):451–453. doi:10.1099/jmm.0.05328-0.
  • Franko B, Vaillant M, Recule C, Vautrin E, Brion JP, Pavese P. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect. 2013;43(4):171–173. doi:10.1016/j.medmal.2013.01.007.
  • Encarnacion CO, Loranger AM, Bharatkumar AG, Almassi GH. Bacterial endocarditis caused by lactobacillus acidophilus leading to rupture of sinus of valsalva aneurysm. Tex Heart Inst J. 2016;43(2):161–164. doi:10.14503/THIJ-15-5121.
  • Boumis E, Capone A, Galati V, Venditti C, Petrosillo N. Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature. BMC Infect Dis. 2018;18(1):65. doi:10.1186/s12879-018-2956-5.
  • Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38(4):457–458. doi:10.1097/00005176-200404000-00017.
  • Guenther K, Straube E, Pfister W, Guenther A, Huebler A. Sever sepsis after probiotic treatment with escherichia coli NISSLE 1917. Pediatr Infect Dis J. 2010;29(2):188–189. doi:10.1097/INF.0b013e3181c36eb9.
  • Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437–439. doi:10.1097/MCG.0b013e318279abf0.
  • Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology. 2015;107(1):56–59. doi:10.1159/000367985.
  • Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–1257. doi:10.1093/ajcn/83.6.1256.
  • Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. Nutrients. 2021;13(7):2382. doi:10.3390/nu13072382.
  • Elias J, Bozzo P, Einarson A. Are probiotics safe for use during pregnancy and lactation? Can Fam Physician. 2011;57:299–301.
  • Jarde A, Lewis-Mikhael AM, Moayyedi P, Stearns JC, Collins SM, Beyene J, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2018;18(1):14. doi:10.1186/s12884-017-1629-5.
  • Gille C, Boer B, Marschal M, Urschitz MS, Heinecke V, Hund V, Speidel S, Tarnow I, Mylonas I, Franz A, et al. Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. Am J Obstet Gynecol. 2016;215(5): 608 e1- e7 doi: 10.1016/j.ajog.2016.06.021.
  • Yang S, Reid G, Challis JRG, Gloor GB, Asztalos E, Money D, Seney S, Bocking AD. Effect of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women. Nutrients. 2020;12(2):12. doi:10.3390/nu12020368.
  • Davidson SJ, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2021;2021(4). CD009951. doi:10.1002/14651858.CD009951.pub3.
  • Fabian E, Kramer L, Siebert F, Högenauer C, Raggam RB, Wenzl H, Krejs G. D-lactic acidosis – case report and review of the literature. Z Fur Gastroenterol. 2017;55(01):75–82. doi:10.1055/s-0042-117647.
  • Munakata S, Arakawa C, Kohira R, Fujita Y, Fuchigami T, Mugishima H. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev. 2010;32(8):691–694. doi:10.1016/j.braindev.2009.09.024.
  • Chp VDA, Jb VG, Szajewska H, Nd E, Hojsak I, Reid D, Shamir R. Probiotics for preterm infants: a strain-specific systematic review and network meta-analysis. J Pediatr Gastroenterol Nutr. 2018;67(1):103–122. doi:10.1097/MPG.0000000000001897.
  • Papagaroufalis K, Fotiou A, Egli D, Tran LA, Steenhout P. A randomized double blind controlled safety trial evaluating d-lactic acid production in healthy infants fed a Lactobacillus reuteri-containing formula. Nutr Metab Insights. 2014;7:19–27. doi:10.4137/NMI.S14113.
  • Lukasik J, Salminen S, Szajewska H. Rapid review shows that probiotics and fermented infant formulas do not cause d-lactic acidosis in healthy children. Acta Paediatr. 2018;107(8):1322–1326. doi:10.1111/apa.14338.
  • Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, Belzer C, Delgado Palacio S, Arboleya Montes S, Mancabelli L, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. 2017;81(4):81. doi:10.1128/MMBR.00036-17.
  • O’mahony SM, Clarke G, Dinan TG, Cryan JF. Early-life adversity and brain development: is the microbiome a missing piece of the puzzle? Neuroscience. 2017;342:37–54. doi:10.1016/j.neuroscience.2015.09.068.
  • Jacobs SE, Hickey L, Donath S, Opie GF, Anderson PJ, Garland SM, Cheong JLY. Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial. BMJ Paediatr Open. 2017;1(1):e000176. doi:10.1136/bmjpo-2017-000176.
  • Stark CM, Susi A, Emerick J, Nylund CM. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68(1):62–69. doi:10.1136/gutjnl-2017-314971.
  • Tun MH, Tun HM, Mahoney JJ, Konya TB, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, et al. Postnatal exposure to household disinfectants, infant gut microbiota and subsequent risk of overweight in children. CMAJ. 2018;190(37):E1097–107. doi:10.1503/cmaj.170809.
  • Karlsson Videhult F, Ohlund I, Stenlund H, Hernell O, West CE. Probiotics during weaning: a follow-up study on effects on body composition and metabolic markers at school age. Eur J Nutr. 2015;54(3):355–363. doi:10.1007/s00394-014-0715-y.
  • Lundelin K, Poussa T, Salminen S, Isolauri E. Long-term safety and efficacy of perinatal probiotic intervention: evidence from a follow-up study of four randomized, double-blind, placebo-controlled trials. Pediatr Allergy Immunol. 2017;28(2):170–175. doi:10.1111/pai.12675.
  • Jackson SA, Schoeni JL, Vegge C, Pane M, Stahl B, Bradley M, Goldman VS, Burguière P, Atwater JB, Sanders ME. Improving end-user trust in the quality of commercial probiotic products. Front Microbiol. 2019;10:739. doi:10.3389/fmicb.2019.00739.
  • U.S. Food & Drug Administration. Current good manufacturing practice, hazard analysis, and risk-based preventive controls for human food. code of federal regulations title 21 2022; Part 117. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=117
  • U.S. Food & Drug Administration. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs. code of federal regulations title 21 2022; Part 210. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=210&showFR=1
  • Shane A, Preidis GA. 2023. Probiotics in the neonatal intensive care unit: a framework for optimizing product standards. Submitted for publication.
  • Smith SM, Wang AT, Katz NP, McDermott MP, Burke LB, Coplan P, Gilron I, Hertz SH, Lin AH, Rappaport BA, et al. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: aCTTION systematic review and recommendations. Pain. 2013;154(7):997–1008. doi:10.1016/j.pain.2013.03.003.
  • Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9(2):e024537. doi:10.1136/bmjopen-2018-024537.
  • Cornelius VR, Sauzet O, Williams JE, Ayis S, Farquhar-Smith P, Ross JR, Branford RA, Peacock JL. Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice. Pain. 2013;154(2):213–220. doi:10.1016/j.pain.2012.08.012.
  • Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437–443. doi:10.1001/jama.285.4.437.
  • Ioannidis JP, Evans SJ, Gotzsche PC, O’neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–788. doi:10.7326/0003-4819-141-10-200411160-00009.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.